Gorrissen Federspiel advised Andera Partners and Kurma Partners in connection with Alveus Therapeutics Inc.’s Series A financing of USD 159.8 million.
Severe obesity is one of the fastest-growing global health challenges, and current treatments can make it difficult for patients to maintain weight loss over time.
Alveus’ lead drug candidate, ALV-100, and the company’s amylin-based pipeline are being developed with a view to delivering sustained efficacy with less frequent dosing, improved tolerability and significantly improved body composition, with the aim of achieving more meaningful outcomes.
The core team from Gorrissen Federspiel consisted of Niels Bang and Caroline Philip.